The secretion of glucagon by islet a cells is normally suppressed by high blood glucose, but this suppressibility is impaired in patients with diabetes or cystic fibrosis (CF), a disease caused by mutations in the gene encoding CF transmembrane conductance regulator (CFTR), a cyclic adenosine monophosphate-activated Cl 2 channel. However, precisely how glucose regulates glucagon release remains controversial. Here we report that elevated glucagon secretion, together with increased glucose-induced membrane depolarization and Ca 2+ response, is found in CFTR mutant (DF508) mice/islets compared with the wild-type. Overexpression of CFTR in AlphaTC1-9 cells results in membrane hyperpolarization and reduced glucagon release, which can be reversed by CFTR inhibition. CFTR is found to potentiate the adenosine triphosphate-sensitive K + (K ATP ) channel because membrane depolarization and whole-cell currents sensitive to K ATP blockers are significantly greater in wild-type/CFTR-overexpressed a cells compared with that in DF508/nonoverexpressed cells. K ATP knockdown also reverses the suppressive effect of CFTR overexpression on glucagon secretion. The results reveal that by potentiating K ATP channels, CFTR acts as a glucosesensing negative regulator of glucagon secretion in a cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes. (Endocrinology 158: 3188-3199, 2017) O pposing the actions of b cell-secreted insulin, glucagon secreted by pancreatic islet a cells plays an essential role in blood glucose maintenance by promoting gluconeogenesis and glycogenolysis in response to blood glucose deprivation or hypoglycemia to increase blood glucose level (1, 2). In addition to stimulating insulin secretion, high blood glucose concentrations inhibit glucagon release via incompletely understood mechanisms thought to involve both direct action on a cells and paracrine effect exerted by factors released by neighboring cells (2, 3). A proper response of glucagon regulation to blood glucose level is a necessary guarantee for glucose homeostasis. Dysregulated glucagon production and/or release, apart from insulin insufficiency, also results in metabolic disorders/diseases, such as hyperglycemia, hypoglycemia, and diabetes mellitus (4-6). However, precisely how
(DF508) mice/islets compared with the wild-type. Overexpression of CFTR in AlphaTC1-9 cells results in membrane hyperpolarization and reduced glucagon release, which can be reversed by CFTR inhibition. CFTR is found to potentiate the adenosine triphosphate-sensitive K + (K ATP ) channel because membrane depolarization and whole-cell currents sensitive to K ATP blockers are significantly greater in wild-type/CFTR-overexpressed a cells compared with that in DF508/nonoverexpressed cells. K ATP knockdown also reverses the suppressive effect of CFTR overexpression on glucagon secretion. The results reveal that by potentiating K ATP channels, CFTR acts as a glucosesensing negative regulator of glucagon secretion in a cells, a defect of which may contribute to glucose intolerance in CF and other types of diabetes. (Endocrinology 158: 3188-3199, 2017) O pposing the actions of b cell-secreted insulin, glucagon secreted by pancreatic islet a cells plays an essential role in blood glucose maintenance by promoting gluconeogenesis and glycogenolysis in response to blood glucose deprivation or hypoglycemia to increase blood glucose level (1, 2) . In addition to stimulating insulin secretion, high blood glucose concentrations inhibit glucagon release via incompletely understood mechanisms thought to involve both direct action on a cells and paracrine effect exerted by factors released by neighboring cells (2, 3) . A proper response of glucagon regulation to blood glucose level is a necessary guarantee for glucose homeostasis. Dysregulated glucagon production and/or release, apart from insulin insufficiency, also results in metabolic disorders/diseases, such as hyperglycemia, hypoglycemia, and diabetes mellitus (4) (5) (6) . However, precisely how glucose regulates glucagon release and whether the secretion is controlled by a mechanism intrinsic to islet a cells remain controversial (7, 8) .
Diabetes is the most common nonpulmonary complication in patients with cystic fibrosis (CF) (9) . CF-related diabetes (CFRD), which is distinct from type 1 and type 2 diabetes mellitus, is associated with increased morbidity and mortality, with a prevalence up to 50% in patients with CF aged 30 years (9) (10) (11) . Patients with CFRD are characterized by impaired glucose tolerance, which is attributed to defects in both islet b2 and a-cell functions, with impaired insulin secretion and decreased suppressibility of pancreatic glucagon secretion (12) (13) (14) (15) . It is generally believed that the gradual deterioration of the pancreatic islet structure due to defective exocrine pancreatic secretion and the obstruction of pancreatic duct underlies the pathophysiology of glucose intolerance in CF (11, 16) . However, our recent study has shown a functional role of the CF transmembrane conductance regulator (CFTR) in pancreatic islet b cells and insulin secretion (17) . We found that the CFTR channel in pancreatic b cells can be activated by glucose and that its Cl 2 efflux contributes to the glucose-induced membrane depolarization and action potentials, leading to Ca 2+ influx required for insulin secretion, a defect of which results in impaired and delayed glucose-induced insulin secretion, as observed in patients with CFRD (11, 17) . CFTR has been found to be expressed in glucagon-secreting human and rodent a cells (18, 19) and was recently implicated in the regulation of glucagon secretion (19) . However, how exactly CFTR regulates glucagon secretion remains elusive, and the effect of CFTR on glucagon secretion has not been demonstrated in vivo at organism level. Using a CFTR mutant (DF508) mouse model (20) and a CFTR-overexpressing AlphaTC1-9 cell line (21, 22) , we undertook the current study to explore the role of CFTR in the regulation of glucagon secretion by a cells. The results demonstrate that CFTR negatively regulates glucagon secretion by potentiating adenosine triphosphate-sensitive K + (K ATP ) channels, a defect of which results in excessive glucagon secretion found in CFTR mutant (DF508) mice/islets. These results suggest that in addition to the previously reported defect in insulin secretion by the b cells (17) , dysregulated glucagon secretion due to CFTR mutations in a cells may also contribute to the glucose intolerance found in CF patients and the pathogenesis of CFRD.
Methods
Animals cftr tm1Kth mice (20) carrying the CFTR mutation, DF508, were kept in a temperature-controlled room with a 12-hour light/dark cycle and were provided with food and water ad libitum in the Laboratory Animal Service Center, the Chinese University of Hong Kong. For glucose tolerance assay, blood was collected from mice via tail vein 12 hours after fasting at 0, 10, and 30 minutes after intraperitoneal injection of glucose (1 g/kg body weight). All procedures were approved by the Animal Ethical Committee of Chinese University of Hong Kong.
Isolation of mouse pancreatic islets
Mouse islets were isolated from 12-to 14-week-old wildtype or DF508 mice, as previously described (17, 23) . Purified islets were cultured in RPMI-1640 medium (Invitrogen, Carlsbad, CA) with 10% fetal bovine serum (FBS), penicillin (100 IU/mL) and streptomycin (100 mg/mL).
Cell culture
The mouse pancreatic a cell line, AlphaTC1 clone 9 (AlphaTC1-9), was purchased from American Type Culture Collection (Manassas, VA) and cultured in Dulbecco's modified Eagle's medium containing 16.7 mM glucose and supplemented with 10% FBS, penicillin (100 IU/mL), and streptomycin (100 mg/mL) at 37°C.
Overexpression and knockdown
AlphaTC1-9 cells were grown till 70% to 80% confluence for transfection. Various DNA plasmids (3 mg per 35-mm 2 dish) or small interfering RNAs (siRNAs; 100 nmol per 35-mm 2 dish) mixed with Lipofectamine 2000 (6 mL per 35-mm 2 dish; Invitrogen) were used for transfection, following the manufacturer's instruction. Cells were collected 48 hours after transfection for other experiments. Plasmid enhanced green fluorescent protein (pEGFP) or pcDNA3.1 conjugated with fulllength human CFTR (pCFTR) or DF508 mutant CFTR were provided by Professor Tzyh-Chang Hwang (University of Missouri, Columbia, MO) and Professor Yoshiro Sohma (Keio University, Tokyo, Japan) (24) (25) (26) . pEGFP and pcDNA3.1 plasmids were used for patch-clamp and imaging experiments, respectively. To enhance fluorescence signal for cell identification in patch-clamp experiments, additional pEGFP (0.5 mg per 35-mm 2 dish) were transfected. Stealth siRNAs targeting mouse SUR1 gene (assay ID MSS277480) and the scrambled nonsilencing siRNA (medium GC content) (catalog no. 12935-300) were purchased from Invitrogen.
Procedure for islet/cell handling and measurement of glucagon by enzyme-linked immunosorbent assay
Glucagon concentrations in mouse plasma or culture media were determined by enzyme-linked immunosorbent assay (ELISA; RayBiotech; catalog EIA-GLU-1), following the manufacturer's instruction. Cells or islets were preincubated in Krebs-Ringer buffer-which contained (in mM) the following: NaCl, 119; KCl, 4.7; CaCl 2 , 2.5; MgSO 4 , 1.2; KH 2 PO 4 , 1.2; NaHCO 3 , 25; HEPES, 10 (pH, 7.4)-with 0.1% bovine serum albumin for 15 minutes at 37°C, followed by 2-hour test incubation in Krebs-Ringer buffer supplemented with glucose (1 to 6 mM) and 0.1% bovine serum albumin. Islets isolated from two to three mice of the same genotype were pooled together; 10 to 20 size-matched islets were selected under a dissecting microscope and grouped as one replicate for ELISA. Adrenaline (10 mM; David Bull Laboratories, Lidcombe, NSW, Australia) and L-arginine (10 mM; Sigma-Aldrich, St. Louis, MO) were also added during the 2-hour test incubation with islets.
Ca
2+ , membrane potential and Cl 2 imaging
Isolated islets were seeded on coverslips coated with poly-Llysine hydrobromide (25 mg/mL) and cultured in RPMI-1640 medium with 10% FBS at 37°C for 3 days. AlphaTC1-9 cells were grown on coverslips until 50% to 60% confluence. For Ca 2+ imaging, islets or cells were incubated at 37°C for 40 minutes with Fura-2 (3 mM; Invitrogen, CA) and Plutonic F-127 (1.5 mM; Invitrogen) in Margo-Ringer solution containing (in mM) the following: NaCl, 130; KCl, 5; MgCl 2 , 1; CaCl 2 , 2.5; HEPES, 20; glucose, 10 (pH, 7.4). Fura-2-loaded cells or islets were transferred to a mini-chamber and mounted onto the fluorescence microscope (Eclipse Ti; Nikon, Tokyo, Japan) equipped with a charge coupled device camera (Spot Xplorer; Diagnostic Instruments, Inc., Sterling Heights, MI). The Xenon lamp (Hamamatsu, Japan) was used to provide a dual excitation at 340 and 380 nm, and emission was collected at 510 nm every 3 seconds. The ratio of 340/380 fluorescent signal intensity indicated the intracellular Ca 2+ changes. Cells in the periphery of the mouse islets (27) were selected as a cells for Ca 2+ imaging and were further confirmed by adrenaline (10 mM) stimulation (28) (29) (30) . For membrane potential (Vm) imaging, cells or islets were bathed in Margo-Ringer solution containing a voltagesensitive dye, DiBAC4 (3) (Dibac, 2.5 mM; Invitrogen). Dibac was excited by 490 nm, and the emission was collected at 520 nm. For calibration of Dibac intensity with Vm changes, a series of incremental concentrations of potassium gluconate (5, 10, 20, 40 , and 60 mM) were added to the bath solution in the presence of valinomycin (2 mM) as previously described (31 
Patch-clamp
Transfected AlphaTC1-9 cells with green fluorescent protein fluorescence were selected under microscope for patch-clamp with an amplifier (Axopatch-200B; Axon Instruments, Foster City, CA) and data acquisition system (DigiData 1322A; Axon Instruments). Borosilicate glass-made patch pipettes (Vitrex, Modulohm A/S, Herlev, Denmark) were pulled on a micropipette puller (P-97; Sutter Instrument Co., Novato, CA) to a resistance of 4 to 7 MV after being filled with pipette solution.
When the whole-cell Giga seal was formed, the capacitance of cell was measured. Cells were bathed in Margo-Ringer solution with 0, 1, or 10 mM glucose, and the pipettes were filled with solution containing (in mM) the following: KCl, 138; NaCl, 10; MgCl 2 , 1; and HEPES, 10; with D-mannitol compensated for 290 mOsm/L. For CFTR currents, cells were bathed in glucosefree Margo-Ringer solution; pipettes were filled with a solution containing (in mM) the following: CsCl, 101; EGTA, 10; HEPES, 10; tetraethylammonium Cl, 20; Mg adenosine triphopshate (ATP), 2; MgCl 2 , 2; glucose, 5.8; osmolality was adjusted to 290 mOsm/L by D-mannitol. To record the membrane voltage, current was clamped to 0.
RNA extraction and conventional and quantitative real-time polymerase chain reaction
Total RNA was extracted by using the TRIzol reagent (Invitrogen), according to the manufacturer's instructions. A total of 1 to 2 mg of total RNA was used with reverse transcripts to obtain complementary DNA by using Molony murine leukemia virus reverse transcription (Promega). The target genes were generated by polymerase chain reaction (PCR) or quantitative PCR with primers (SUR1: forward, 
Western blotting
Cells were lysed with radioimmunoprecipitation assay buffer (150 mM NaCl, 50 mM Tris-Cl, 1% nonyl phenoxypolyethoxylethanol , 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate) containing protease inhibitor cocktail (Roche, Mannheim, Germany; catalog no. 11697498001) for 30 minutes on ice. Supernatant was collected as total protein after centrifugation at 14,000 rpm for 30 minutes. Protein were separated by sodium dodecyl sulfatepolyacrylamide gel electrophoresis and blotted onto nitrocellulose membrane. Rabbit anti-CFTR antibody (Alomone, catalog no. ACL-006, 1:500; RRID: AB_2039804); rabbit anti-b-tubulin (Santa Cruz, catalog no. sc-9104, 1:2000; RRID: AB_2241191) were used ( Table 1 ). The protein bands were visualized with ECL Western blotting detection reagent (GE Healthcare, Little Chalfont, UK), following manufacturer's instructions, and scanned by densitometer.
Statistical analysis
Data are presented as mean 6 standard error of the mean. Two-tail unpaired Student t tests were used for two groups of comparison. For three or more groups, data were analyzed by one-way analysis of variance, followed by the Tukey post hoc test. Interactions involving two groups were analyzed by twoway analysis of variance. A P value ,0.05 was considered to indicate statistical significance.
Results

Elevated glucagon levels in CFTR mutant mice
To explore the role of CFTR in regulating blood glucagon level, we used a CFTR mutant mouse model with a DF508 mutation (20) , the major CFTR mutation found in .70% of patients with CF (32). After fasting for .12 hours, DF508 mice showed significantly higher blood glucagon levels, as measured by ELISA, than those in wild-type mice [ Fig. 1(a) ]. We also conducted a glucose tolerance test in these mice and measured blood glucagon levels at 10 and 30 minutes after glucose administration. As shown in Fig. 1(a) , DF508 mice exhibited consistently higher levels of glucagon than did wild-type mice. This in vivo result suggests that CFTR mutation may lead to dysregulated blood glucagon levels, contributing to glucose intolerance in CF.
Mutation or inhibition of CFTR increases glucagon secretion by isolated mouse islets ex vivo
To further investigate the role of CFTR in pancreatic islet a cells and exclude the contribution from other sources, we performed ex vivo experiments in isolated mouse islets. Significant suppression of glucagon release was observed in wild-type islets when treated with a high level of glucose (6 mM), compared with that with 1 mM [ Fig. 1(b) ]. At both glucose concentrations, treatment of the islets with a CFTR inhibitor, Inh172 (10 mM), for 2 hours significantly elevated glucagon levels [ Fig. 1(b) ], which were similar to levels observed in DF508 islets [ Fig. 1(b) ]. These results are consistent with a suppressive role of CFTR in glucagon secretion.
Overexpression of CFTR suppresses glucagon secretion in AlphaTC1-9 cell line
Because insulin is known to inhibit glucagon release (33), the glucagon increase in isolated islets noted above, with either CFTR mutation or inhibition, might not be due to a direct effect of CFTR on a cells but rather might be secondary to its direct effect on insulin secretion by the b cells, as previously reported (17) . To investigate a direct effect of CFTR on glucagon release, we overexpressed CFTR in a mouse a cell line, AlphaTC1-9, which was used in the studies for glucagon secretion (21, 22) . As shown in Fig. 2 (a) and 2(b), CFTR was successfully overexpressed at both protein and channel function ELISA measurement of glucagon release from isolated WT or DF508 mouse islets after incubation for 2 hours in low-glucose (1 mM) or high-glucose (6 mM) solution in the presence or absence of a CFTR inhibitor, Inh172 (10 mM). n is shown in each column. Data are mean 6 standard error of the mean. ***P , 0.001, *P , 0.05, t test.
levels. Because CFTR channel function in a cells has not been reported, we used the patch-clamp technique to examine the whole-cell currents in CFTRoverexpressing AlphaTC1-9 cells. The K + in the pipette solution was replaced by Cs + , leaving Cl 2 as the major permeant ion that mediates the whole-current detected. Because CFTR can be activated by cyclic adenosine monophosphate, we used forskolin (10 mM), an activator of adenylyl cyclase, to stimulate the cells and detected substantial current activation, with time-and voltage-independent whole-cell current profile and a linear I-V relationship typical of CFTR, in CFTR-overexpressing AlphaTC1-9 cells but not the vector-control cells [ Fig. 2(b) ]. The forskolin-induced currents could be blocked by the CFTR inhibitor GlyH (10 mM) [ Fig. 2(b) ], indicative of CFTR currents. When bathed in 1 mM glucose incubation bath, the CFTRexpressing cells showed significantly reduced glucagon release as compared with the cells transfected with empty vectors. The CFTR overexpression-induced glucagon suppression was significantly reversed by the CFTR inhibitor GlyH (10 mM), shown in Fig. 2(c) . Taken together, the results obtained from CFTR-overexpressing a cells are consistent with those from CFTR mutant mice and isolated islets, revealing a role of CFTR in suppression of glucagon secretion.
CFTR suppresses glucose deprivation-induced Ca 2+ increase Physiologically, glucose deprivation induces a series of complex electrical activities in islet a cells, including membrane depolarization and Ca 2+ influx, which are known to be required for glucagon release through exocytosis (28 Fig. 3(a) ], and at the end of each experiment we added adrenaline to confirm that the observed [Ca 2+ ] i activities were from a cells [ Fig. 3(a) ] because adrenaline is known to induce [Ca 2+ ] i increases only in a cells, but not other cell types in the islet (29) . As shown in Fig. 3(a) , both wild-type and DF508 cells showed an increase in [Ca 2+ ] i in response to a change in extracellular glucose from 6 to 1 mM. However, the glucose deprivation-induced [Ca 2+ ] i response was significantly higher in DF508 islet a cells than in wild-type cells [ Fig. 3(a) entry, the inhibitory effect of CFTR on glucose deprivation-induced Ca 2+ response might be due to its effect on Vm. We therefore also compared the changes in Vm induced by glucose deprivation in isolated islets from DF508 and wild-type mice. Again, islet peripheral cells were selected as a cells for Vm measurement. As shown in Fig. 3(b) , deprivation of glucose (from 6 to 1 mM) gave rise to membrane depolarization (increases in Dibac signal) in both wild-type and DF508 islet peripheral cells. Note that glucose reduction results in membrane hyperpolarization in b cells (17) , and, thus, the observed depolarization in response to glucose deprivation in these islet peripheral cells should be originated from a cells but not b cells. Similar to the Ca 2+ response, DF508 islet a cells, as shown in Fig. 3 in ADR-responsive cells Figure 3 . Suppression of glucose deprivation-induced Ca 2+ influx and membrane depolarization by CFTR in islet a cells. (a) Intracellular Ca 2+ measurement by Fura-2 in isolated wild-type (WT) or DF508 mouse islets challenged with glucose deprivation from 6 to 1 mM; representative responses over time are shown. Fluorescence image shows a representative Fura-2-loaded mouse islet with selected peripheral cells (circled) for Fura-2 340/380 ratio detection. Adrenaline (ADR, 10 mM) was added at the end of each experiment, with responsive cells considered a cells; statistical summary of their responses to glucose deprivation in WT and DF508 is shown on the right. n is shown in each column. ***P , 0.001, t test. (b) Membrane depolarization assessed by Dibac, a voltage-sensitive fluorometric, in isolated WT or DF508 mouse islets in response to glucose deprivation from 6 to 1 mM; representative responses over time are shown. Fluorescence image shows an isolated mouse islet loaded with Dibac, with circled cells selected for the detection. Change in Dibac fluorescence intensity was calibrated into membrane voltage change (DVm) and compared between WT and DF508. n is shown in each column. ***P , 0.001, t test. Data are mean 6 standard error of the mean. Bars in fluorescence images, 100 mm.
[ Fig. 4(b) ]. This suggests that in the presence of 10 mM glucose, when CFTR is presumably activated, as demonstrated in Fig. 4(a) Fig. 5(a) ]. Although these results are in line with a suppressive role of CFTR in glucagon release, it is puzzling that CFTR-overexpressing a cells are more hyperpolarized in contrast to the more depolarized Vm previously observed in b cells (17) , although CFTR in both cell types exhibits similar glucose sensitivity and mediates Cl 2 efflux under the same conditions. In fact, the measured resting Vm by the patch-clamp experiments in a cells showed greater hyperpolarization in cells exposed to high glucose (10 mM), when CFTR is supposed to be activated, than seen with low glucose (0 mM), when CFTR activity is low. Opposite results should have been observed if CFTR were solely responsible for the Vm changes. Other channel(s) must be contributing to the hyperpolarizing effect of CFTR in a cells. Because activation of the g-aminobutyric acid A (GABA A ) receptor, also a chloride channel, has been reported to suppress glucagon secretion in islet a cells (33), we tested possible involvement of GABA A receptor in mediating the effect of CFTR in a cells. The results showed that treatment with bicuculline (10 mM), a GABA A receptor antagonist, did not alter the suppressive effect of CFTR overexpression on glucagon secretion in AlphaTC1-9 cells (Supplemental Fig. S1 ), excluding the involvement of GABA A receptor. CFTR suppresses glucagon secretion by potentiating K ATP channel activity in a cells K ATP channels, which are inhibited by high glucose with the increase in ATP/adenosine diphosphate (ADP) ratio but open when the ATP/ADP ratio is low at glucose deprivation, have been proposed as a key glucose-sensing mechanism in a cells with Na + and Ca 2+ channels as the downstream mediators regulating glucagon release (7, 8) ; however, their precise role remains obscure. Interestingly, CFTR has been reported to interact and modulate other ion channels (37, 38) , including the ROMK (kir1.1), one type of K ATP (39). Thus, it is possible that in addition to its To test this, we first examined K ATP expression and found similar expression levels of K ATP genes, SUR1 and Kir6.2, in AlphaTC1-9 cells with or without CFTR expression (Supplemental Fig. S2 ). We next used patch-clamp to measure Vm in AlphaTC1-9 cells with or without CFTR overexpression, in conjunction with the use of glibenclaminde (GLIB), a selective K ATP blocker. The results showed that in the low-glucose (1 mM) bath, GLIB (100 mM) induced Vm depolarization in AlphaTC1-9 cells with the CFTRoverexpressing pCFTR cells exhibiting a significantly greater response (22.3 6 3.5 mV) than that of control cells (pVector, 11.6 6 0.6 mV) [ Fig. 5(b) ]. Similar results were observed with use of Dibac measurement on isolated islets; the wild-type a cells showed greater depolarizing response to K ATP inhibition by another blocker, tolbutamide (100 mM) (Supplemental Fig. S3 ), as compared with DF508 a cells. We further measured K ATP currents in AlphaTC1-9 cells. A series of voltages (280 to 220 mV) were applied to elicit K ATP currents in the presence of CFTR inhibitor (Inh172) to exclude CFTR currents. As shown in Fig. 5(c) , at 10 mM glucose, pCFTR-expressed cells showed significantly larger whole-cell currents that were sensitive to GLIB (100 mM), consistent with a role of CFTR in potentiating K ATP activity in a cells.
To confirm that the suppressive effect of CFTR on glucagon secretion involves K ATP channels, we knocked down the functional subunit of K ATP , SUR1, in the CFTRoverexpressing AlphaTC1-9 cells by SUR1-targeting siRNAs. The success of transfections was confirmed by RT-PCR and quantitative PCR, showing upregulation of CFTR and downregulation of SUR1 [ Fig. 6(a) ]. We then compared the glucagon released from CFTR-overexpressing AlphaTC1-9 cells with or without K ATP knockdown. As shown in Fig. 6(b) , knockdown of K ATP subunit substantially reversed the suppressive effect of CFTR overexpression on glucagon release induced by low (1 mM) or high (6 mM) glucose, confirming the involvement of K ATP channels in the suppressive action of CFTR in a cells. Representative time course recording of patch-clamp measurements of Vm in AlphaTC1-9 cells transfected with pCFTR or pVector in 1 mM glucose bath before and after addition of a K ATP blocker, GLIB (100 mM). Pipettes were filled with KCl-containing pipette solution. Statistical summary of GLIBinduced Vm changes (DVm) is shown on the right. n is shown in each column. *P , 0.05, t test. (c) Representative patch-clamped whole-cell currents and corresponding I-V curves elicited by a series of voltages (280 to 220 mV) from a holding voltage of 270 mV in AlphaTC1-9 cells transfected with pCFTR or pVector in 10 mM glucose, before (Ctrl) and after the addition of Inh172 (10 mM) or, subsequently, GLIB (100 mM). n = 3 to 6. (d) Summary of GLIB-sensitive whole-cell current density, which was obtained by subtracting the current after treatment with GLIB from the current in the presence of Inh172, at 280 mV, 260 mV, and 240 mV in AlphaTC1-9 cells with pCFTR or pVector. n = 3 to 4. Data are mean 6 standard error of the mean. *P , 0.05, t test.
Discussion
The present results reveal a suppressive role of CFTR in the regulation of glucagon secretion, providing a mechanism intrinsic to pancreatic a cells. The results obtained from the CFTR/DF508-overexpressing a cells, in addition to that obtained from wild-type and DF508 mice/ isolated islets, have clearly demonstrated that glucagon secretion can be regulated intrinsically by a cells, with CFTR as a key player in suppressing glucagon release-CFTR mutation/inhibition at the animal, tissue, or cell level consistently results in elevated levels of glucagon secretion compared with that observed in the wild-type mice/islets or CFTR-overexpressing cells. These results are consistent with a recent report that demonstrates an inhibitory role of CFTR in regulating glucagon release in both mouse and human islet a cells (19) . However, the previous study did not provide experimental evidence to explain how CFTR can exert an inhibitory role on glucagon secretion by acting as a Cl 2 channel.
Our present finding has demonstrated that the suppressive effect of CFTR on glucagon secretion is attributed to a more hyperpolarized Vm and a smaller degree of glucose deprivation-induced depolarization and Ca 2+ response observed in wild-type/CFTRoverexpressing a cells (in islets or cell line) compared with that observed in DF508/CFTR inhibited cells.
Compared with what we previously reported in b cells (17) , similar features of CFTR are observed in a cells. In both types of cells, CFTR is activated by glucose, which could be explained by glucose-induced ATP production (40, 41) and secondarily cyclic adenosine monophosphate increase (42) (43) (44) or glucose-dependent kinases (45, 46) , although detailed activation mechanism remains to be elucidated. In addition, CFTR appears to mediate Cl 2 efflux in both cell types. Although Cl 2 currents are usually thought to be inhibitory (33, 47) , CFTR-mediated Cl 2 efflux depolarizes membrane potential and contributes to the electrical spikes promoting insulin secretion in b cells (17) . However, the present results suggest that CFTR plays a suppressive role in glucagon secretion in a cells. These results present a paradox in CFTR function, while with similar channel characteristics, stimulating insulin secretion in b cells but inhibiting glucagon secretion in a cells. Interestingly, the same paradox is also observed for K ATP channels. Although it has been well established that glucose-induced closure of K ATP channels in b cells is crucial for insulin secretion, the same condition inhibits glucagon release in a cells, making their role in the process controversial (7, 48) . Of note, recent studies have suggested that K ATP closure may cause depolarization that inactivates voltage-dependent Na + channel and thus prevent glucagon release (7, 8) . In this regard, CFTRmediated Cl 2 efflux might similarly lead to depolarization and inactivate Na + channels. However, instead of depolarization, the present findings show that CFTR contributes to a hyperpolarized Vm, through its potentiating effect on K ATP , as evidenced by the greater sensitivity to the K ATP channel blocker in Vm or whole-cell current measurements observed in CFTR-overexpressing or wild-type islet a cells compared with that of vectoroverexpressing or DF508 cells [ Fig. 5(b) and Supplemental Fig. S3 ]. The involvement of K ATP channel in mediating the suppressive action of CFTR on glucagon secretion is further supported by the reversal of the suppressive effect of CFTR overexpression with the knockdown of K ATP channels in the a cell line. The currently demonstrated CFTR-potentiated K ATP activation should be sufficient to close the Na + channel or prevent its activation, but not to reduce the inactivation or CFTR in AlphaTC1-9 cells after transfection with pVector, pCFTR, siRNAs targeting SUR1 (siSUR1), or nonsilencing control siRNAs (siNC). n = 3. ***P , 0.001, one-way analysis of variance. (b) Levels of glucagon release from AlphaTC1-9 cells transfected with pVector, pCFTR, siSUR1, or siNC, in low-glucose (1 mM) or high-glucose (6 mM) solution. n = 3 to 9. ***P , 0.001, *P , 0.05, t test. Data are mean 6 standard error of the mean. GAPDH, glyceraldehyde 3-phosphate dehydrogenase; mRNA, messenger RNA; ns, not significant.
of Na + channel, as previously reported (7, 8) . Therefore, the CFTR-potentiated K ATP activity results in suppressed glucagon secretion, providing a suitable solution to the paradox of K ATP playing seemingly controversial roles in a and b cells. The question remains as to how CFTR potentiates K ATP . CFTR interacts with multiple membrane proteins (49) (50) (51) and is reported to modulate K ATP (kir1.1) activity in the kidney through protein-protein interaction (52) . Thus, similar mechanism may also apply to a cells; this awaits further investigation.
With our findings taken together, we propose a working model for regulating glucagon release intrinsic to a cells involving both CFTR and K ATP channels (Fig. 7) . In this model, activation of CFTR by high glucose, presumably by elevated intracellular ATP/ADP ratio as previously reported by others (53) (54) (55) (56) , leads to activation of K ATP channels overcoming the inhibitory effect of ATP/ADP on K ATP channels, which results in a strong hyperpolarization that diminishes the Ca 2+ response required for glucagon release, as observed in the current study. In the case of DF508 or CFTR inhibition, the potentiating effect of CFTR on K ATP channels is removed, resulting in enhanced depolarization required for Ca 2+ response, and thus enhanced glucagon release, which was consistently observed in the current study with DF508 mice/islets/cells. This model not only explains how CFTR exerts an inhibitory effect on glucagon release in a cells but also provides a solution to a long-standing puzzle regarding how K ATP channels inhibit glucagon release under a glucose concentration known to suppress their function. The present finding suggests that it is not the glucose-induced closure of K ATP channels but rather the potentiation of K ATP channels by CFTR in response to a rise in glucose that underlies glucose-induced glucagon suppression. Given the recognized key roles of K ATP , such as governing Vm and triggering Na + inactivation, in regulating glucagon secretion by a cells (7, 8) , the unexpected CFTR involvement and its potentiating effect on K ATP channels in a cells provides a mechanism regulating a cell glucagon secretion.
What are the clinical implications of the present findings? The importance of CFTR in regulating blood glucose is highlighted by the presence of glucose intolerance in patients with CF, which has been attributed to defects in both b and a cell functions, among other contributing factors (11) . In addition to impaired insulin secretion (57) (58) (59) , glucagon suppression following oral glucose administration is increasingly impaired, with decreasing glucose tolerance, in patients with CF (14, 12, 60) . The current study, which demonstrates the importance of glucose-activated CFTR in suppressing glucagon release and the inability of DF508 mice/islets to suppress glucagon release, explains the reduced glucose suppressibility found in many patients with CF. Because insulin from b cells can also exert an inhibitory effect on a cell glucagon release (33, (61) (62) (63) , a defect in insulin secretion due to defective CFTR (57, 64, 65) , may also contribute to the impaired glucagon suppressibility in CF.
The results of the current study, together with our previous finding in b cells (17) , suggest a dual role of CFTR in regulating glucagon secretion, a direct action on a cells, and an indirect effect through insulin from b cells. Therefore, both defects in insulin and glucagon secretion may contribute to glucose intolerance in CF and the development of CFRD. Of note, glucose suppressibility is also impaired or absent in patients with type 1 and type 2 diabetes mellitus (5, 66, 67) . The currently demonstrated critical role of CFTR in suppressing glucagon secretion suggests a plausible cause of diabetic conditions due to abnormal CFTR expression/function in the general 2 efflux, activated CFTR potentiates K ATP channel activity, which overcomes the direct inhibitory effect of glucose on the K ATP channel, resulting in Vm hyperpolarization (Vm↓) and hence inhibits Ca 2+ influx through voltage-dependent Ca 2+ channel (VDCC) and suppresses glucagon secretion. (b) When CFTR is defective (i.e., DF508 mutation), the potentiation effect of CFTR on K ATP is removed, leading to a more depolarized Vm (Vm↑) as a result of glucose-induced K ATP closure, and thus VDCC activation and excessive glucagon secretion. population other than CF, which warrants future investigation.
